Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income: 2015-2025

Historic Other Non Operating Income for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $253.

  • Sunshine Biopharma's Other Non Operating Income fell 98.33% to $253 in Q3 2025 from the same period last year, while for Sep 2025 it was -$337,359, marking a year-over-year decrease of 214.02%. This contributed to the annual value of -$44,082 for FY2024, which is 17892.65% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Other Non Operating Income of $253 as of Q3 2025, which was down 86.96% from $1,940 recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Other Non Operating Income high stood at $286,535 for Q2 2024, and its period low was -$340,003 during Q4 2024.
  • Over the past 3 years, Sunshine Biopharma's median Other Non Operating Income value was $40 (recorded in 2023), while the average stood at -$3,789.
  • The largest annual percentage gain for Sunshine Biopharma's Other Non Operating Income in the last 5 years was 109,883.52% (2024), contrasted with its biggest fall of 871,702.56% (2024).
  • Sunshine Biopharma's Other Non Operating Income (MRQ) stood at -$7,909 in 2021, then skyrocketed by 100.32% to $25 in 2022, then crashed by 256.00% to -$39 in 2023, then crashed by 871,702.56% to -$340,003 in 2024, then surged by 100.07% to $253 in 2025.
  • Its Other Non Operating Income stands at $253 for Q3 2025, versus $1,940 for Q2 2025 and $451 for Q1 2025.